Granules India gets EIR from USFDA for Bonthapally facility; stock climbs 5%

The USFDA has issued an Establishment Inspection Report (EIR) for Bonthapally facility located at Hyderabad, Telangana, India.

Sep 12, 2019 03:09 IST India Infoline News Service

Granules India
Shares of Granules India jumped 5% after the pharma company received an Establishment Inspection Report (EIR) from USFDA for Bonthapally unit.

The USFDA has issued EIR for the Bonthapally facility located at Hyderabad, Telangana, India, the company said in a press note.

This facility was inspected by USFDA in July 2019 and there was one observation during the inspection. The Bonthapally facility is one of the world’s largest single-site Paracetamol API manufacturing plant by volume.

Along with Paracetamol APIs, the company has established Metformin and Guaifenesin API manufacturing plants in the same facility, the company added.

Granules India Ltd is currently trading at Rs104.55, up by Rs5.55 or 5.61% from its previous closing of Rs99 on the BSE.

Related Story